# Sen-Jam Private Investor Campaign — Early Momentum Incentives Now Open | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/349181
- Entity ID: wefunder:feed_item:349181
- Published at: 2026-07-08 13:07:09 UTC
- Updated at: 2026-07-09 06:48:57 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors,We have quietly opened our Reg D 506(b) campaign on Wefunder and are now ready to increase the ask.To date, we have raised approximately $133,000 during a very soft opening. We are grateful to the first three investors who stepped forward early, and we want to make sure they are fully protected and rewarded as we now open the next phase of the campaign.Our goal is ambitious but clear: raise up to $3 million over the next 90 days to support Sen-Jam’s next stage of growth.This capital comes at an important moment for the company. Our scientific proof continues to build, Galaxy is advancing, Atlas is coming into focus, and our story is becoming bigger than any single asset. We are building a computational resilience platform designed to accelerate the discovery and development of inflammation-resolution therapeutics that help people live longer, healthier, more resilient lives.Why Early Momentum MattersWefunder has milestone triggers at approximately:$250,000, $500,000, $1 million, and $2 millionAt each of those levels, Wefunder sends a dedicated "curated" email to its accredited investor base (Total Active ~ 50,000).That means our first objective is to move quickly from $133,000 to $250,000, unlock the first Wefunder milestone, and create broader momentum for the campaign.Early Investor Common Share IncentiveTo reward investors who help us create that early momentum, we are introducing a declining common share acceleratortied to campaign milestones.The earlier you invest, the greater the incentive.Current Base Common Share PerksNew Milestone AcceleratorIn addition to the base perk above, investors will receive the following accelerator based on when they invest:For example, an investor who invests $100,000 before we reach the $250,000 milestone would receive the standard 4% base common share perk, plus the 15% early accelerator, for a total common share incentive equal to 19% of the investment amount.An investor who invests $150,000 or more before the $250,000 milestone would receive the standard 5% base common share perk, plus the 15% early accelerator, for a total common share incentive equal to 20% of the investment amount.We are also extending this same highest incentive treatment to the first three investors who helped us open the campaign, so they are not disadvantaged by moving first.Current Offering TermsThe current financing is being conducted through a convertible note on Wefunder with:$150 million valuation cap, 20% discount, 8% interest $10,000 minimum investment→ You can view the private offering using this Wefunder link→ Schedule a call with me: calendly.com/jiversenWhy NowWe believe Sen-Jam is entering one of the most important periods in our company’s history.Our work has evolved from a pipeline of individual drug programs into a broader platform opportunity. We are combining clinical evidence, inflammation-resolution biology, drug repurposing, and AI-enabled discovery to identify new therapeutic opportunities across recovery, chronic disease, metabolic health, addiction medicine, respiratory health, critical care, and longevity.We are building toward a bigger stage for a bigger story.This private campaign is designed to help us fund that next stage and create the momentum needed for our broader fall capital strategy.If you have been considering increasing your investment in Sen-Jam, this first milestone window provides the strongest incentive we intend to offer during this campaign.Thank you for your continued belief, trust, and support.With gratitude,JimForward-looking statements: This update contains forward-looking statements regarding planned milestones, regulatory interactions, partnerships, valuation, and timing. These statements reflect current expectations and involve risks and uncertainties; actual outcomes, dates, and valuations may differ materially. Nothing in this communication is a guarantee of future results, valuation, or investment performance. This communication is intended for accredited investors and should be read together with the official offering materials.